GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) Files An 8-K Other EventsItem 9.01 Other Events.
On September 25, 2017, Gemphire Therapeutics Inc. (“Gemphire”) issued a press release announcing the presentation of the Phase 2b COBALT-1 clinical data at the 2017 FH Global Summit in Miami, Florida.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Current Report on Form 8-K, and the inclusion of such website addresses in this Current Report on Form 8-K by incorporation by reference of the press release is as inactive textual references only.
|
Item 9.01
|
Financial Statements and Exhibits.
|
Gemphire Therapeutics Inc. ExhibitEX-99.1 2 gemp-20170925ex9918d5179.htm EX-99.1 Gemp_8-K_Ex_991 Exhibit 99.1 Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit COBALT-1 results show significant LDL-C lowering for FH patients,…To view the full exhibit click here
About GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP)
Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.